Daniel O'Day (AP Images)

With the pric­ing ball in Gilead’s court, ICER of­fers some pa­ra­me­ters on how it can be played — an­a­lyst sees at least '$1B in the­o­ry'

When asked di­rect­ly on Gilead’s re­cent earn­ings call whether the com­pa­ny ex­pects to prof­it from remde­sivir — the on­ly an­tivi­ral to have gen­er­at­ed pos­i­tive clin­i­cal da­ta on a ran­dom­ized, place­bo-con­trolled tri­al and earned An­tho­ny Fau­ci’s en­dorse­ment as a stan­dard-of-care — Daniel O’Day was care­ful not to com­mit.

“(T)here is no guide book out there, there is no rule book out there,” the CEO said, pledg­ing on­ly to be “very thought­ful” about pro­vid­ing ac­cess.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.